Materia Medica Holding
Clinical trials sponsored by Materia Medica Holding, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Hope for women with chronic cystitis: raphamin trial aims to stop recurring UTIs Results expected Dec 2026 (estimated)
-
New sleep tablet MMH-450 enters first human safety trial
Symptom relief CompletedThis Phase 1 trial evaluates the safety and tolerability of MMH-450, an experimental tablet that dissolves under the tongue, in 18 healthy adults aged 18 to 45 with normal sleep habits. Participants take the drug daily for 7 days while researchers monitor for side effects. The st…
Phase 1 • Sponsor: Materia Medica Holding • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Could a new dissolving tablet quiet coughs? safety trial begins
Knowledge-focused CompletedThis early-stage trial is testing whether an experimental drug called MMH-522 is safe and tolerable for healthy people. About 16 volunteers aged 18 to 45 will take the tablet daily for 7 days, and researchers will monitor them for any side effects. The goal is to gather initial s…
Phase 1 • Sponsor: Materia Medica Holding • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC